54368-19-3

Basic information

• Product Name: (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER
• Synonyms: (4-Oxo-4H-quinazolin-3-yl)-acetic acid methyl ester; 3(4H)-quinazolineacetic acid, 4-oxo-, methyl ester; Methyl (4-oxoquinazolin-3(4H)-yl)acetate
• CAS NO: 54368-19-3
• Molecular Formula: C₁₁H₁₀N₂O₃
• Molecular Weight: 218.21
• Mol File: 54368-19-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 373.8°C at 760 mmHg
• Flash Point: 179.9°C
• Appearance: /
• Density: 1.29g/cm³
• Vapor Pressure: 8.75E-06mmHg at 25°C
• Refractive Index: 1.605
• CAS DataBase Reference: (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER(54368-19-3)
• EPA Substance Registry System: (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER(54368-19-3)

Safety Data

• Hazardous Substances Data: 54368-19-3(Hazardous Substances Data)

Usage

Description

(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is a chemical compound with the molecular formula C11H10N2O3. It is an ester derivative of acetic acid and contains a quinazolin-4-one moiety. (4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER may have potential applications in the pharmaceutical industry due to its quinazolinone core, which has been reported to exhibit various biological activities such as anticancer, anti-inflammatory, and antifungal properties. The ester functional group in this compound suggests that it may have some degree of lipophilicity, which could affect its solubility and distribution in biological systems. Further research and testing are required to fully understand the properties and potential uses of this compound.
Used in Pharmaceutical Industry:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a potential pharmaceutical agent for its reported biological activities. The quinazolinone core of this compound has been associated with anticancer, anti-inflammatory, and antifungal properties, making it a candidate for the development of new drugs targeting these therapeutic areas.
Used in Drug Development:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a starting material or intermediate in the synthesis of more complex drug molecules. Its quinazolinone core and ester functional group can be further modified or combined with other chemical entities to create new compounds with improved pharmacological properties.
Used in Research and Testing:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a research compound to study its biological activities and potential therapeutic applications. Further research is required to understand its properties, mechanism of action, and safety profile, which can inform the development of new drugs based on this compound.
Used in Medicinal Chemistry:
(4-OXO-4H-QUINAZOLIN-3-YL)-ACETIC ACID METHYL ESTER is used as a scaffold or template in medicinal chemistry for the design and optimization of new drug candidates. Its quinazolinone core and ester functional group can be modified to explore structure-activity relationships and identify compounds with improved potency, selectivity, and pharmacokinetic properties.

InChI:InChI=1/C11H10N2O3/c1-16-10(14)6-13-7-12-9-5-3-2-4-8(9)11(13)15/h2-5,7H,6H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 14663-53-7 3-carboxymethyl-3,4-dihydro-4(1H)-quinazolinone 
• 64-18-6 formic acid 
• 82185-40-8 2-amine-N-(methoxycarbonylmethyl)benzamide 
• 67-56-1 methanol 
• 149-73-5 trimethyl orthoformate 
• 118-48-9 isatoic anhydride 
• 2981-86-4 3-(2-hydroxyethyl)quinazolin-4(3H)-one 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 491-36-1 4-quinazolinol 
• 28144-70-9 anthranilic acid amide 
• 491-36-1 4-Hydroxyquinazoline 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 14663-53-7 3-carboxymethyl-3,4-dihydro-4(1H)-quinazolinone 
• 783371-69-7 3,4-dihydro-3-[(1R,2S,5R)-menthoxycarbonylmethyl]-4(1H)-quinazolinone 
• 108086-38-0 2-(4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide 

Relevant articles and documents

Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity

There has been significant interest in developing a transient receptor potential A1 (TRPA1) antagonist for the treatment of pain due to a wealth of data implicating its role in pain pathways. Despite this, identification of a potent small molecule tool possessing pharmacokinetic properties allowing for robust in vivo target coverage has been challenging. Here we describe the optimization of a potent, selective series of quinazolinone-based TRPA1 antagonists. High-throughput screening identified 4, which possessed promising potency and selectivity. A strategy focused on optimizing potency while increasing polarity in order to improve intrinisic clearance culminated with the discovery of purinone 27 (AM-0902), which is a potent, selective antagonist of TRPA1 with pharmacokinetic properties allowing for >30-fold coverage of the rat TRPA1 IC50 in vivo. Compound 27 demonstrated dose-dependent inhibition of AITC-induced flinching in rats, validating its utility as a tool for interrogating the role of TRPA1 in in vivo pain models.

Mukaiyama's reagent promoted C-N bond formation: a new method to synthesize 3-alkylquinazolin-4-ones

A new approach to synthesize 3-alkylquinazolin-4-ones is developed. Treatment of quinazolin-4-ones with Mukaiyama's reagent, a base and a primary amine nucleophile results in the formation of 3-alkylquinazolin-4-ones in moderate to good yields under mild conditions. Using this methodology, a one-step synthesis of the natural alkaloid, echinozolinone, is accomplished.